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Understanding how genetic risk variants contribute to complex diseases is crucial for predicting disease
susceptibility and developing patient-tailored therapies. In this issue of Cell Stem Cell, Young et al. (2015)
dissect the function of common non-coding risk haplotypes in the SORL1 locus in the pathogenesis of
sporadic Alzheimer’s disease using patient-derived induced pluripotent stem cells.Alzheimer’s disease (AD) is themost com-
mon neurodegenerative disease and is
characterized by progressive cognitive
dysfunction and memory impairment.
While the pathogenesis of AD remains
elusive, the discovery of rare forms of
familial AD (FAD) caused by dominant
mutations in proteins such as amyloid
precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2) have
provided fundamental insights into the
pathophysiology of AD and suggest that
alterations in APP processing lead to
the deposition of amyloid beta (Ab) and
trigger neuronal dysfunction and cellular
degeneration (Bertram et al., 2010; Goate
and Hardy, 2012). Although the vast ma-
jority of AD cases are not linked to known
genetic mutations, common pathological
features between familial and sporadic
forms of the disease such as Ab-contain-
ing amyloid plaques and neurofibrillary
tangles indicate a central role of alter-
ations in APP processing in the pathogen-
esis of sporadic AD (SAD). Epidemiology
and population genetics suggest that
SAD results from complex interactions
between genetic risk variants and envi-
ronmental factors.
Understanding the pathogenesis of
sporadic diseases such as SAD that lack
a clear genetic component has been chal-
lenging due to the absence of reliable
experimental models, which would reca-
pitulate relevant features of the underlying
disease. Human induced pluripotent stem
cells (hiPSCs) have been proposed as an
ideal tool to overcome this limitation by
providing patient-derived disease rele-
vant cells that carry all the genetic alter-
ations that contribute to the disease
(Soldner and Jaenisch, 2012). Over thelast few years, hiPSC-based studies
have provided valuable insight into the
molecular mechanisms of disease devel-
opment for numerous monogenetic dis-
orders, but little progress has been
achieved in understanding sporadic dis-
eases due to the complex and heteroge-
neous nature of the underlying genetics
and disease-associated pathologies. In
particular technical and biological hetero-
geneity due to differences in genetic
background and variations in hiPSC isola-
tion and in vitro differentiation limit a
reliable classification of in vitro disease-
associated phenotypes (Soldner and Jae-
nisch, 2012). While genome-wide associ-
ation studies (GWASs) have identified
numerous genetic variants associated
with an increased risk of developing SAD
(Lambert et al., 2013), mechanistic in-
sights into the role of the majority of these
risk variants for disease development are
largely lacking. Advancing from genetic
association to biological function has
been challenging because the majority of
GWAS-identified variants are non-coding,
which considerably impedes our ability
to generate relevant animal models for
sporadic disease. In addition, a major
challenge of using human-derived cells
is that risk variants are not only present
in patients but also in unaffected individ-
uals, albeit with lower frequency. This
inevitably implies that individual risk
variants are not sufficient to cause dis-
ease-associated phenotypes in carrier in-
dividuals (Figure 1A) or in hiPSCs derived
from carriers or patients.
In this issue of Cell Stem Cell, Young
and colleagues use patient-derived
hiPSCs to dissect the effect of common
SAD-associated non-coding genetic vari-Cell Stem Ceants in the 50 region of the SORL1 (sortilin-
related receptor, L[DLR class], A-repeats
containing) gene on disease risk. SORL1
is a neuron-specific receptor implicated
in intracellular vesicular trafficking and is
thought to be involved in APP processing
by directing APP to endocytic pathways
for recycling (Offe et al., 2006; Spoelgen
et al., 2006). While reduced expression
of SORL1 in the brain of SAD patients
has been reported previously (Scherzer
et al., 2004), initial experiments were un-
able to identify a consistent correlation
between SORL1 expression and either
disease status (unaffected individuals
compared to SAD patient-derived cells)
or risk haplotype (cell lines carrying
SAD-associated risk variants compared
to cell lines carrying protective variants)
in a panel of hiPSC-derived neural precur-
sor cells and neurons. This is not unex-
pected given the known cell-to-cell vari-
ability in cultures of differentiated cells
and the unpredictable effect of uncharac-
terized genetic modifier loci on cellular
phenotypes in hiPSCs derived from unre-
lated patients (Soldner and Jaenisch,
2012). However, when the authors
analyzed the effect of brain-derived neu-
rotrophic factor (BDNF) on hiPSC-derived
neurons, they detected a significant cor-
relation between the SAD-associated
SORL1 haplotype and the BDNF-depen-
dent response of SORL1 expression: neu-
rons from individuals carrying at least
one protective SORL1 allele responded
with increased SORL1 expression to
BDNF treatment in contrast to neurons
derived from individuals homozygous
for the haplotype associated with in-
creased risk of developing SAD, which
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Figure 1. Risk-Haplotype-Dependent In Vitro Disease Modeling of SAD
(A) Distribution of common SORL1 risk haplotype in SAD patients (dark color) and unaffected individuals
(light color). Red represents individuals with a haplotype associated with a higher risk for SAD (Risk); blue
represents individuals with a haplotype associated with a reduced risk for SAD (Protective).
(B) Stratification according to SORL1 haplotype (risk versus protective haplotype) indicating that risk
haplotype does not predict disease status of carriers.
(C) Cellular phenotypes indicating the absence of both BDNF-dependent upregulation of SORL1 and
associated reduction of Ab peptide in hiPSC-derived neurons from individuals carrying the SAD-associ-
ated SORL1 risk haplotype.
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Previewsof SORL1 correlated with alterations in
APP processing as indicated by a signifi-
cant reduction of Ab peptides in cell lines
carrying the protective alleles (Figures
1B and 1C). In addition, RNAi-mediated
knockdown of SORL1 prevented BDNF-
dependent reduction of Ab peptides in
cells from individuals carrying the protec-
tive haplotype, whereas ectopic overex-
pression of SORL1 by itself was sufficient
to reduce Ab expression in non-respon-
sive cell lines. This is consistent with the
notion that BDNF-dependent alterations
in APP processing are mediated by
changes in SORL1 expression.
These data suggest a model in which
cis-regulatory effects of genetic variants
in the 50-region of the SORL1 locusmodu-
late the BDNF-mediated response of
SORL1 expression and, subsequently,
the production of Ab peptides (Figure 1).
Given that genomic duplications of APP
are sufficient to cause development of
dominant FAD, the observed modest
reduction of Ab peptides by 20%–30%
is consistent with the concept of a
decreased lifetime risk of developing
SAD in individuals carrying the protective
haplotype. These results also add new
mechanistic insight into the possible role
of neurotrophins such as BDNF in the
pathogenesis of SAD, suggesting that it
is not the expression of BDNF per se but
rather the individual’s regulatory seq-342 Cell Stem Cell 16, April 2, 2015 ª2015 Eluence-dependent response that might
alter the risk of disease. One important
implication that is particularly relevant for
the future design of similar experiments
is that the observed cellular disease-rele-
vant phenotypes are not associated with
actual disease status but rather with the
presence or absence of genetic risk vari-
ants (Figure 1). This is in agreement with
the ‘‘common disease-common variant
hypothesis’’ which proposes that multiple
risk variants with small effect size in com-
bination with additional environmental
factors are the drivers of sporadic dis-
eases (Gibson, 2012). Finally, the results
emphasize that the study of sporadic dis-
eases by hiPSC technology will require a
more precise population-genetics-based
stratification of patients and hypothesis-
driven approaches to identify disease-
relevant phenotypes.
The potential of personalized medicine
to predict disease susceptibility and
response to patient-tailored therapies is
tempered by our inability to functionally
connect the growing number of disease-
associated genetic variants to specific
disease phenotypes. Young and col-
leagues not only provide newmechanistic
insights with potential diagnostic and
therapeutic implications for SAD but also
demonstrate a new and important avenue
of how to study sporadic diseases in a
dish. However, a major limitation of thissevier Inc.approach is that risk haplotypes are
merely correlated with cellular pheno-
types without the identification of the
functionally causal and disease-relevant
genetic variant. Recent progress in pre-
dicting functional regulatory elements in
the non-coding part of the genome based
on genome-wide epigenetic information
(Kundaje et al., 2015) and the ability to effi-
ciently genetically modify the genome of
human cells using site-specific nucleases
such as CRISPR/Cas9 genome editing
will eventually allow us to prioritize and
systematically analyze the function of
non-coding risk variants in controlled
isogenic in vitro systems.ACKNOWLEDGMENTS
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